Larubrilstat is a vascular non-inflammatory molecule-1 (VNN1) inhibitor.

Laporolimus is an immunosuppressant.

Kibdelone C is a flavonoid compound found in Kibdelosporangium sp. with anticancer activity, exhibiting GI50 values of less than 1 nM against leukemia cell lines (SR) and renal cancer cell lines (SN12C). Kibdelone C is promising for anticancer research.

KB-208 is a phagocytosis inhibitor that improves immune thrombocytopenia (ITP) in mouse models at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum toxicity biomarkers. KB-208 can be used in immunology research.

Fenoxazoline is a decongestant and a vasoconstrictor.

FA-15 is an phenolic antioxidant. FA-15 has effect on stabilization of reactive fuels.

Ethyl 4-(butylamino)benzoate is an N-alkylated ester derivative of aminobenzoic acid.

DL-Theanine (DL-Glutamic acid γ-ethyl amide) is a natural compound showing tranquilizing effects in the brain.

Cumyl-chsinaca is a synthetic cannabinoid containing indazole-3-carboxamide

BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC50 of 0.1 μM. BPH-742 has antitumor activity.

BPH-628 is an aromatic geranylgeranyl diphosphate synthase (GGPPS) inhibitor, with a pIC50 of 6.1.

BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases.

Amidepin is a new type of antiarrhythmic compound. Amidepin has the activity of regulating cardiac electrical activity. The main regulatory mechanism of amidepin involves ion channel or receptor interaction. Amidepin can be used for the study of arrhythmias.

5,5-Diphenylbarbituric acid is an organic compound belonging to the derivatives of barbituric acid. 5,5-Diphenylbarbituric acid can be used for seizure study.

4F-Docetaxel (4FDT) is a fluorinated docetaxel analog. 4F-Docetaxel has anti-hepatoma activity and can be used for research of hepatocellular carcinoma (HCC).

DC360 is a synthetic retinoid analogue of all-trans retinoic acid (ATRA) which induces RARβ expression. DC360 can be utilized in characterization of retinoid signalling pathways.

BMS-185354 is a selective RARγ activator with an EC50 value of 28 nM. BMS-185354 is promising for research of cancers.

Onapristone is a progesterone receptor antagonist, with Kds of 11.6 nM and 11.90 nM for human endometrium and myometrium progesterone receptor in saturation analysis. Onapristone has antitumor activity.

11α-Hydroxytestosterone is a deriviative of Hydrocortisone, with the relative binding affinity to progesterone receptor of 9% (comparing to R5020119384) 100%). 11α-Hydroxytestosterone inhibits the growth and differentiation of human decidual cells in culture.

SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and partial PPARγ agonist. SP-C01 can inhibit Ser273 phosphorylation.

SKLB102 shows a high affinity with PPARγ. SKLB102 has potent ability to reduce fat deposition and protect liver against non-alcoholic fatty liver disease (NAFLD) through regulating adipocytokine expression and preventing insulin resistance.

PT-S58, a GSK0660 derivative, is a PPARβ/δ full antagonist with an IC50 value of 98 nM. PT-S58 inhibits the agonist-induced transcriptional activity of PPARβ/δ in vitro.

MHY 553 is a PPARα agonist that is effective when taken orally. MHY 553 helps alleviate liver fat accumulation by increasing fatty acid oxidation and reducing inflammation during the aging process. MHY 553 inhibits the accumulation of triglycerides induced by liver X receptor agonists in HepG2 cells. MHY 553 significantly suppresses the expression of inflammatory mRNA in aging rats.

E0924G is an orally active activator for PPARδ with EC50 of 2.82 μM. E0924G promotes the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibites F-actin ring formation in RAW264.7 macrophages. E0924G regulates the bone density and bone loss in ovariectomized (OVX) and age-related osteoporosis models.

DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes.

Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC50s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

Apo-12'-lycopenal is a Lycopene metabolite. Apo-12'-lycopenal promotes adipocyte differentiation and adiponectin secretion via PPAR-γ activation.

Amezalpat is the antagonist for PPARα with IC50 of 58 nM. Amezalpat exhibits antineoplastic activity.

AD-5075 is an orally active insulin sensitizer. AD-5075 mediates its antidiabetic activity by binding to PPARγ and thereby generating an active conformation of the receptor.

9(10)-Nitrooleate (9(10)-Nitrated oleic acid) is a nitrated derivative of Oleic acid. 9(1